PA21 Safety and Efficacy in Adult Chinese Subjects

Study Overview
=================
Brief Summary
-----------------
This study evaluates the efficacy of PA21 in comparison with sevelamer carbonate (Renvela®) in lowering and maintaining serum phosphorus in adult Chinese subjects with CKD on dialysis after 12 weeks of treatment.

Detailed Description
-----------------
Primary Objective is to evaluate the efficacy of PA21 in comparison with sevelamer carbonate (Renvela®) in lowering and maintaining serum phosphorus in adult Chinese subjects with CKD on dialysis after 12 weeks of treatment. In addition , secondary objectives include evaluating the efficacy of PA21 and sevelamer carbonate over time as the percentage of subjects with serum phosphorus within the target range of 1.13 to 1.78 mmol/l (3.5 to 5.5 mg/dl) and to compare the safety and tolerability of PA21 versus sevelamer carbonate (Renvela®). In total, 286 patients (143 patients to PA21 treatment and 143 patients to sevelamer carbonate treatment) will be randomised with a screening period: up to 4 weeks and a washout period of up to 3 weeks. Treatment period (total duration 12 weeks) will include a dose titration period and a maintenance period of an open-label, active-controlled comparison of PA21 versus sevelamer carbonate for 4 weeks. The primary efficacy assessment will be a non-inferiority assessment of the 2 groups of subjects at Week 12 in terms of serum phosphate lowering capability. There will be a follow-up period of 30 days after last dosing. The investigational treatments will be a PA21 dose group of PA21 chewable tablets standardised to contain 500 mg of iron. PA21 contains approximately 20% m/m of elemental iron. All doses of PA21 are expressed in mg of iron. The Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted , provided a subject has been receiving that dose for a minimum of 2 weeks and for safety or tolerability reasons at any time. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day). The active control is sevelamer carbonate, Renvela®, tablets, containing 800 mg of sevelamer carbonate. The starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) are permitted, provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time. The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).

Official Title
-----------------
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 and Sevelamer Carbonate (Renvela®) in Chinese CKD Patients With Hyperphosphataemia

Conditions
-----------------
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia

Intervention / Treatment
-----------------
* Drug: PA21
* Drug: sevelamer carbonate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chinese subjects receiving either maintenance haemodialysis (HD) or peritoneal dialysis (PD) for at least 12 weeks prior to screening. No home HD or nocturnal HD (overnight stay at site) will be allowed Subjects with a history of hyperphosphataemia (HP). Subjects with serum phosphorus levels >5.5 mg/dl (>1.78 mmol/l) at screening or during the washout period. Male and female adult subjects (aged ≥18 years at time of consent). Subjects with the ability to understand the requirements of the study and abide by the study restrictions, and who agree to return for the required assessments (in the Investigator's opinion). Subject (or legally acceptable representative) has provided the appropriate written informed consent. Subject must provide written informed consent before any study-specific procedures are performed including screening procedures. Exclusion Criteria: Subjects with intact parathyroid hormone (iPTH) levels >800 ng/l (>800 pg/ml or 88 pmol/l) at screening. Subjects with iPTH >600 ng/l (>600 pg/ml or 66 pmol/l) at screening must be considered stable (in the Investigator's opinion). Subjects with planned or expected parathyroidectomy within the next 6 months (in the Investigator's opinion). Subjects on peritoneal dialysis (PD) with a history of peritonitis in the last 3 months or ≥3 episodes in the last 12 months. Subjects with serum total calcium >10.5 mg/dl (>2.6 mmol/l) or <7.6 mg/dl (1.9 mmol/l) at screening. Subjects with: Any history of major gastrointestinal (GI) surgery likely to influence the outcome of treatment with PBs Clinically significant, active GI disorders (e.g., active peptic ulcer, Crohn's disease, colitis ulcerative, irritable bowel syndrome, intestinal motility disorder (symptomatic gastroparesis (during treatment or untreated), intestinal obstruction, moderate/severe constipation (including persistent symptoms with regular use of laxatives or enemas and limitations in activities of daily living), intestinal pseudo-obstruction, megacolon, mechanical obstruction)) or any GI disorders under medical treatment. Clinically significant, active hepatic disorders or any hepatic disorder under medical treatment Subjects currently with (in the Investigator's opinion): Swallowing difficulties/dysphagia Estimated life expectancy of less than 12 months Anticipated renal transplantation during study participation Subjects with known seropositivity to human immunodeficiency virus or positive HIV test at screening. Subjects with active/current fulminant hepatitis B infections and/or hepatitis C virus ribonucleic acid positivity at screening. Subjects with a history of haemochromatosis or other iron accumulation disorders that might lead to iron overload. Subjects with serum ferritin >800 mcg/l (1,797.6 pmol/l) or transferrin saturation (TSAT) >50% at screening. Subjects with raised alanine aminotransferase or aspartate aminotransferase >3 times the upper limit of the normal range at screening. Subject is taking any prohibited medication(s) which cannot be stopped at least one week before study treatment start. Prohibited medications include: oral calcium supplements, any drugs/agents having a phosphate binding action that contain aluminium, magnesium or calcium (apart from hyperkalaemia drugs), phosphate binders in addition to sevelamer carbonate), nicotinamide, oral iron products, oral vitamins containing iron and other oral iron containing supplements (See Section 7.7). Subject has known hypersensitivity and/or intolerance to any of the study products to be administered. Subject has previously been randomised into this study. Subject is currently enrolled in or has completed any other investigational device or drug study <30 days prior to screening, or is receiving other investigational agent(s). Subjects who are pregnant (e.g., positive human chorionic gonadotropin test) or breastfeeding. Subjects of childbearing potential, not using adequate contraceptive precautions must agree to use a highly effective method of birth control during the study and for 1 month after the last dose of study medication. Subject has a history of drug or alcohol abuse within 2 years prior to screening. Subject has a significant medical conditions or anticipated need for major surgery during the study, which (in the Investigator's opinion), may be associated with increased risk to the subject, or may interfere with study assessments or outcomes, or the ability to provide informed consent or comply with study procedures.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Open-label, Randomised, Active-controlled, Parallel Group, Multicentre,
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PA21 tablets containing 500 mg of iron<br>PA21 chewable tablets standardised to contain 500 mg of iron. PA21 500 mg (iron) chewable tablet contains approximately 2.5 g PA21 drug substance (sucroferric oxyhydroxide). Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day). | Drug: PA21<br>* sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.<br>* Other names: Velphoro®;|
| Active Comparator: Sevelamer carbonate: Renvela® tablets<br>Starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day). | Drug: sevelamer carbonate<br>* sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.<br>* Other names: Renvela®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum phosphorus (mmol/l ) | Change from baseline in serum phosphorus levels at Week 12: comparison between PA21 group and sevelamer carbonate group. | baseline and 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum phosphorus (mmol/l ) | Serum phosphorus levels at each time point and change from baseline (BL) | baseline, weeks 1, 2, 4, 6, 8, 12 | 
| Serum phosphorus (mmol/l) | % of subjects with serum phosphorus within 1.13 to 1.78 mmol/l | baseline, weeks 1, 2, 4, 6, 8, 12 | 
| Adverse events (AEs) | Frequency of AEs determined by seriousness, severity and relatedness to study drugs | baseline, weeks 1, 2, 4, 6, 8, 12 | 
| Diarrhoea. | Frequency of AE of special interest - diarrhoea. | baseline, weeks 1, 2, 4, 6, 8, 12 | 
| Withdrawals due to AEs | Percentage of withdrawals due to AEs | baseline, weeks 1, 2, 4, 6, 8, 12 | 
| Serum calcium (mmol/l) | Serum total calcium levels at each time point and change from baseline | baseline, weeks 1, 2, 4, 6, 8, 12 | 
| Hypercalcemia (mmol/l) | Percentage of subjects that develop at least 1 episode of sustained hypercalcaemia (>10.0 mg/dl; >2.5 mmol/l) during study participation | baseline, weeks 1, 2, 4, 6, 8, 12 | 
| Serum iPTH (pg/ml) | Serum iPTH levels at specified time points and change from baseline | baseline, weeks 8, 12 | 
| Serum iron (mcg/dl) | Serum iPTH levels at specified time points and change from baseline | baseline, weeks 4, 8, 12 | 
| Serum ferritin (mcg/l) | Serum ferritin levels at specified time points and change from baseline | baseline, weeks 4, 8, 12 | 
| Serum transferrin (mcg/dl) | Serum transferrin measured at specified timepoints | baseline, weeks 4, 8, 12 | 
| Transferrin saturation (TSAT) (%) | TSAT measured at specified timepoints | baseline, weeks 4, 8, 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Kidney Disease, Hyperphosphatemia, Dialysis